Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase.

× No keyword cloud information.

8 in total

1. 3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release.

Authors: P C Waldmeier; J Lauber; W Blum; W J Richter
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1981-01 Impact factor: 3.000

2. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.

Authors: A M O'Carroll; C J Fowler; J P Phillips; I Tobbia; K F Tipton
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1983-04 Impact factor: 3.000

3. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.

Authors: N A Garrick; D L Murphy
Journal: Psychopharmacology (Berl) Date: 1980 Impact factor: 4.530

4. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.

Authors: M J Heeringa; F d'Agostini; P DeBoer; M DaPrada; G Damsma
Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575

5. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors: K Baraczka; M I Fekete; B Kanyicska
Journal: J Neural Transm Date: 1983 Impact factor: 3.575

Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase.

1. 3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release.

2. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.

3. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.

4. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.

5. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

6. Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors.

Review 7. Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.

8. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis.